The 2028 campaign is already heating up. For Democrats, it's not clear which state will go first.

The dramatic rise of Nvidia stock since 2022 has massively benefitted this tech-focused investment trust. But should I invest ...

"attachment_1199068" align="aligncenter" width="1456"] A pharmacy worker distributing prescription medicines to ...

The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.

Akero Therapeutics Inc. (NASDAQ: AKRO) is one of the best mid cap pharma stocks to buy. On July 16, AstraZeneca announced ...

This week's episode covers news about Sarepta, babies born following mitochondrial transfer, and AI identifying therapy targets.

A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's inhaler for the treatment of a chronic lung condition, the drugmaker said on Friday.

The new inhaler replaces Trixeo Aerosphere’s existing gas propellant with a low global warming-potential alternative.

In this article, you’ll find some of the top content that was published on LCGC this week, including an ASMS 2025 retrospective and an overview of microplastic research.

AstraZeneca's shares are up 3.5% over the year to date but remain down 11% over the past 52 weeks.

Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, & Head of Development starting Aug 2025.

Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.